**Coronavirus Disease 2019 (COVID-19)**

Updated twice weekly on Tuesdays and Fridays, and current as of 3:00 p.m. on the date it was posted.

This document is a collation of resources for your reference. For official guidance on COVID-19 in Ontario, please visit the [Ministry of Health](http://www.health.gov.on.ca).

**Table of Contents**

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Content</td>
<td>3</td>
</tr>
<tr>
<td>Public Health Agencies</td>
<td>3</td>
</tr>
<tr>
<td>Public Health Agency of Canada</td>
<td>canada.ca</td>
</tr>
<tr>
<td>BC Centre for Disease Control</td>
<td>bccdc.ca</td>
</tr>
<tr>
<td>Institut national de santé publique</td>
<td>3</td>
</tr>
<tr>
<td>CDC: Centers for Disease Control and Prevention</td>
<td>cdc.gov</td>
</tr>
<tr>
<td>ECDC: European Centre for Disease Prevention and Control</td>
<td>ecdc.europa.eu</td>
</tr>
<tr>
<td>FDA: U.S. Food &amp; Drug Administration</td>
<td>fda.gov</td>
</tr>
<tr>
<td>Public Health England</td>
<td>gov.uk</td>
</tr>
<tr>
<td>World Health Organization</td>
<td>who.int</td>
</tr>
<tr>
<td>Other relevant government bodies / health care organizations</td>
<td>5</td>
</tr>
<tr>
<td>Center for Infectious Disease Research Policy</td>
<td>cidrap.umn.edu</td>
</tr>
<tr>
<td>National Collaborating Centre for Environmental Health</td>
<td>ncceh.ca</td>
</tr>
<tr>
<td>Updated Daily</td>
<td>7</td>
</tr>
<tr>
<td>COVID-19 resources (case counts)</td>
<td>arcgis.com</td>
</tr>
<tr>
<td>COVID-19 Canada Open Data Working Group</td>
<td>COVID-19 CODWG</td>
</tr>
<tr>
<td>Johns Hopkins CCSE</td>
<td>systems.jhu.edu</td>
</tr>
<tr>
<td>NextStrain</td>
<td>nextstrain.org</td>
</tr>
<tr>
<td>Guidelines and Technical documents (updated weekly)</td>
<td>7</td>
</tr>
<tr>
<td>Section I: General Guidelines</td>
<td>7</td>
</tr>
<tr>
<td>Ontario / Canada Main Page</td>
<td>7</td>
</tr>
<tr>
<td>Reopening/Rebuilding Guidelines</td>
<td>7</td>
</tr>
</tbody>
</table>
New Content

Public Health Agencies

Public Health Agency of Canada | canada.ca

Instead of daily case counts and vaccinations, starting the week of December 6, 2021 we will be reporting weekly trends. For daily case counts, you can still check 2019 novel coronavirus: outbreak update, or COVID-19 vaccination in Canada for vaccination rates.

- Key COVID updates [12-19-2022]
  - Weekly change in cases: 16,528
  - Total cases: 4,457,366
  - Weekly change in deaths: 249
  - Total deaths: 48,645
  - Weekly tests reported: 93,704
  - Weekly percent positivity: 12.6%
- COVID-19 daily epidemiology update [updated regularly]

BC Centre for Disease Control | bccdc.ca

- In-patient algorithm for management of COVID-19 [12-14-2022]
- Antimicrobial and immunomodulatory therapy in adult patients with COVID-19 [updated 12-14-2022]

Institut national de santé publique | inspq.qc.ca

- Protection contre l’hospitalisation due à la COVID-19 conférée par la vaccination et l'infection antérieure chez les personnes de 60 ans et plus [12-21-2022]
- SRAS-CoV-2 : Mesures de prévention et contrôle des infections pour les unités d’hémodialyse [12-19-2022]
- SRAS-CoV-2 : Mesures de prévention, de contrôle et de gestion des éclissions pour tous les milieux de soins [12-19-2022]
- SRAS-CoV-2 : Procédures de nettoyage et de désinfection de l’environnement et des équipements de soins pour les cliniques médicales/cliniques externes/centres désignés de dépistage/GMF [12-19-2022]
- SRAS-CoV-2 : Mesures de prévention et contrôle des infections en présence d’un cas suspecté ou un cas de COVID-19 en milieux de courte durée, de longue durée, de réadaptation et de santé mentale [12-19-2022]
- SRAS-CoV-2 : Assises scientifiques soutenant les recommandations sur les mesures de prévention et contrôle des infections [12-19-2022]
- SRAS-CoV-2 : Mesures de prévention et contrôle des infections pour les soins à domicile [12-19-2022]

**CDC: Centers for Disease Control and Prevention | cdc.gov**

- COVID Data Tracker recent updates - 2022-12-22 - the 2020-2021 Nationwide COVID-19 Infection- and Vaccination-Induced Antibody Seroprevalence (Blood donations) page was updated with estimates for April-June 2022. [12-22-2022]
- COVID Data Tracker recent updates - 2022-12-22 - the Rates of COVID-19 Cases and Deaths by Vaccination Status page was updated with data on COVID-19 cases through November 19, 2022, and death data through October 29, 2022 from 23 U.S. jurisdictions, representing 50% of the total U.S. population. [12-22-2022]
- COVID Data Tracker recent updates - 2022-12-22 - a new summary data table was added to COVID Data Tracker’s Trends in Cases and Deaths by Race/Ethnicity, Age, and Sex tab and to data.cdc.gov. The new table does not include new data; rather, the table will allow users to download data from the visualization. [12-22-2022]
- COVID Data Tracker recent updates - 2022-12-22 - the Pediatric Seroprevalence page was updated to display combined seroprevalence (vaccine-induced and infection-induced). Before this update, the page only included infection-induced seroprevalence. [12-22-2022]
- COVID Data Tracker recent updates - 2022-12-22 - the Vaccination Equity page was updated to display "At Least One Dose" options for the total population and the populations ages <18 years, greater than or equal to age 18 years, and greater than or equal to age 65 years. A new "Updated (Bivalent) Booster Dose" option was also made available for the population ages 5-17 years, greater than or equal to age 18 years, and the population greater than or equal to age 65 years. [12-22-2022]
- COVID Data Tracker recent updates - 2022-12-22 - the Vaccinations in Nursing Homes page was updated with two new visualizations displaying data on nursing home residents and staff who are up to date with COVID-19 vaccines. [12-22-2022]
- Overall US COVID-19 vaccine distribution and administration update as of Wed, 21 Dec 2022 06:00:00 EST [12-21-2022]

**ECDC: European Centre for Disease Prevention and Control | ecdc.europa.eu**

  - “At the end of week 50 (week ending 18 December 2022), the pooled EU/EEA notification rate of COVID-19 cases among people aged 65 years and older increased by 7% compared with the previous week, reaching 43% of the maximum value reported during the pandemic. This trend is driven by 15 of the 24 countries that reported data on this indicator, many of which have observed sharp increases (median 27%, range 6–43%) compared with the previous week. The European COVID-19 Forecast Hub forecasts increases in reported cases in more than half of countries in the period to week 52, 2022.
  - The impact of this increased transmission is being seen in hospitals: 11 of the 21 countries with data on hospital or ICU admissions/occupancy up to week 50 reported an increasing trend in at least one of these indicators compared to the previous week. Four countries reported increases in deaths, although the pooled EU/EEA death rate decreased by 11% compared to the previous week, with 2 009 deaths reported in the past week.
Increased inter-generational mixing during the year-end holiday season is likely to increase the exposure of vulnerable groups to respiratory viruses. The holidays will also bring about changes in reporting, testing, and healthcare-seeking behaviour, which will complicate the interpretation of epidemiological data submitted in the coming weeks. ECDC is planning to update this report by 13 January 2023 (data reported up to week 1, 2023).

The cumulative uptake of a first booster was 65.3% (country range: 11.3–86.9%) among adults aged 18 years and older, 84.8% (country range: 13.3–100.0%) among people aged 60 years and older and 54.6% (country range: 9.2–75.7%) in the total population. The cumulative uptake of a second booster was 15.5% (country range: 0.1–41.4%) among adults aged 18 years and older, 33.1% (country range: 0.3–85.7%) among people aged 60 years and older and 12.7% (country range: 0.1–33.2%) in the total population.

Among the seven countries with an adequate volume of sequencing or genotyping for weeks 48–49 (28 November to 11 December 2022), the estimated distribution of variants of concern (VOC) or of interest (VOI) was 52.0% (37.9–72.5% from five countries) for BQ.1, 31.1% (19.2–94.3% from seven countries) for BA.5, 8.2% (3.7–18.9% from seven countries) for BA.2.75, 6.5% (2.2–10.5% from five countries) for XBB, 1.0% (0.3–1.9% from seven countries) for BA.4 and 0.6% (0.3–8.0%, 688 detections from seven countries) for BA.2.

Data on COVID-19 vaccination in the EU/EEA [updated regularly]

FDA: U.S. Food & Drug Administration | fda.gov
- Coronavirus (COVID-19) update: daily roundup [updated regularly]
- FDA to hold Advisory Committee meeting to discuss future vaccination regimens addressing COVID-19 [12-16-2022]

Public Health England | gov.uk
Note: Public Health England was replaced by UK Health Security Agency and Office for Health Improvement and Disparities. These organizations are listed below under “Other relevant government organizations”
- Location of Public Health England (PHE) functions from 1 October 2021

World Health Organization | who.int

Other relevant government bodies / health care organizations
- Government of Ontario
  - All Ontarians aged 5+ eligible for bivalent booster [12-15-2022]
- Indigenous Services Canada
  - Coronavirus (COVID-19) and Indigenous communities [updated regularly]
• Statistics Canada
  o COVID-19: a data perspective [updated regularly]
  o Coronavirus (COVID-19) testing for adult social care services [updated 12-15-2022]

• UK Health Security Agency
  o Consensus statements and medium-term projections on COVID-19 [updated 12-23-2022]
  o The R value and growth rate [updated 12-23-2022]
  o COVID-19 test validation approved products [updated 12-23-2022]
  o Consensus statements and medium-term projections on COVID-19 [updated 12-23-2022]
  o Infection prevention and control in adult social care: COVID-19 supplement [updated 12-23-2022]
  o National flu and COVID-19 surveillance reports published [updated 12-22-2022]
  o COVID-19 testing procurement [12-21-2022]
  o National protocol for Comirnaty® 10 microgram/dose COVID-19 mRNA vaccine [updated 12-14-2022]

• UK Department of Health and Social Care
  o UK cements 10-year-partnership with Moderna in major boost for vaccines and research [12-22-2022]
  o Expiry date of Paxlovid (nirmatrelvir and ritonavir) antiviral medication extended [12-21-2022]
  o Expiry date of Lagevrio (molnupiravir) antiviral medication extended [updated 12-20-2022]
  o COVID-19 PPE guide for adult social care services and settings [updated 12-15-2022]

• UK Medicines and Healthcare products Regulatory Agency
  o Sanofi Pasteur COVID-19 vaccine authorised by MHRA [12-21-2022]
  o Regulatory approval of COVID-19 vaccine VidPrevtyn Beta [updated 12-21-2022]
  o Coronavirus (COVID-19) vaccines adverse reactions [updated 12-21-2022]
  o Medical devices given exceptional use authorisations during the COVID-19 pandemic [updated 12-19-2022]

• UK Office for National Statistics

Center for Infectious Disease Research Policy | cidrap.umn.edu
• Molnupiravir doesn’t cut Omicron hospitalization, death but can speed recovery [12-22-2022]
• Global COVID cases remain stable but rise in two regions [12-22-2022]
• Estimate says 19 million US adults have long COVID [12-21-2022]
• COVID vaccine efficacy against infection in kids dropped amid Omicron [12-20-2022]
• Study: Wearing surgical masks over N95s can cause dangerous leaks [12-20-2022]
• COVID vaccine more effective than infection against death, hospital care, study finds [12-19-2022]
• Drugs that fight inflammation, clots tied to better 6-month COVID-19 survival [12-19-2022]
• Bivalent COVID-19 boosters may cut risk of severe disease by more than half [12-16-2022]
• Study links COVID-related hardships to more traumatic stress among moms [12-16-2022]
US flu activity shows signs of declining; COVID indicators mixed [12-16-2022]

National Collaborating Centre for Environmental Health | ncceh.ca
- December research scan with COVID-19 sections [12-14-2022]
- November research scan with COVID-19 sections [11-24-2022]
- October research scan with COVID-19 sections [10-20-2022]

ProMED | promedmail.org
- Latest on COVID-19 [individual posts]

Updated Daily

COVID-19 resources (case counts) | arcgis.com
- Canada COVID-19

COVID-19 Canada Open Data Working Group | COVID-19 CODWG
- COVID-19 in Canada (case count dashboard)

Johns Hopkins CCSE | systems.jhu.edu
- 2019-nCoV Global Cases (by Johns Hopkins CSSE) [real-time tracking]
- Resetting our response: changes needed in the US approach to COVID-19 [07-29-2020]

NextStrain | nextstrain.org
- Phylogeny of SARS-like betacoronaviruses including novel coronavirus (nCoV) [real-time tracking]
- Genomic epidemiology of novel coronavirus (nCoV) [real-time tracking]
- Genomic analysis of nCoV spread. Situation report 2020-01-30 [real-time tracking]

Guidelines and Technical documents (updated weekly)
The guidelines listings are current to 10-26-2022; posted 10-28-2022

Section I: General Guidelines

Ontario / Canada Main Page
- Ontario guidance
- Canadian guidance (federal)

Reopening/Rebuilding Guidelines

Ontario
- ON COVID-19 public health measures and advice [no date]

Canada (federal) and provinces and territories (other than Ontario)
• CA Guidance for a strategic approach to lifting restrictive public health measures [06-10-2022]
• CA COVID-19: readiness criteria and indicators for easing restrictive public health measures [05-14-2021]
• BC B.C.'s response to COVID-19 [updated 10-12-2022]
• AB COVID-19 public health actions [no date]
• SK Living with COVID [no date]
• MB Manitoba Pandemic Response System [no date]
• QC Coronavirus disease (COVID-19) in Québec [08-17-2022]
• NB Living with COVID-19 [no date]
• NL Current Restrictions [no date]
• PEI COVID-19 (coronavirus) in Prince Edward Island [no date]
• NS Reopening plan [updated regularly]
• NW COVID-19 [no date]
• YT Forging ahead: the Yukon's continuing response to COVID-19 [no date]
• NT Nunavut’s Path: Living with COVID-19 [no date]
• Guidance on re-opening northern, remote, isolated, and Indigenous communities [no date]

WHO
• Implementation guidance for assessments of frontline service readiness [07-01-2021]
• Considerations for implementing and adjusting public health and social measures in the context of COVID-19: interim guidance [06-14-2021]

ECDC
• Data on country response measures to COVID-19 [updated 08-25-2022]
• Transitioning beyond the acute phase of the COVID-19 pandemic: approaches and tools used by a sample of EU countries in the transition and de-escalation phase – interim report [04-27-2022]
• Introducing a coherent European framework for tuning COVID-19 response measures [03-17-2021]

Vaccinations- General

Ontario Ministry of Health
• COVID-19 vaccine-relevant information and planning resources [updated 10-17-2022]
• Ethical framework for COVID-19 vaccine distribution [archived] [updated 04-27-2022]

Canada (Federal)
• Updated guidance on COVID-19 vaccine booster doses in Canada [updated 10-07-2022]
• Archived 39: Recommendations on the use of bivalent Omicron-containing mRNA COVID-19 vaccines [updated 10-07-2022]
• COVID-19 drugs and vaccines [updated 09-16-2021]
• Planning guidance for immunization clinics for COVID-19 vaccines [09-22-2022]
• Interim guidance on planning considerations for a fall 2022 COVID-19 vaccine booster program in Canada [06-29-2022]
• Summary of NACI statement of June 29, 2022 [06-29-2022]
• Adjusting public health measures in the context of COVID-19 vaccination [updated 06-27-2022]
• Health care provider vaccine tool kit, version 3 [06-10-2022]
• An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI): Initial guidance on a second booster dose of COVID-19 vaccines in Canada [04-05-2022]
• COVID-19 vaccine guide for youth and adults (12 years and over): Overview [08-11-2022]
• An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) guidance on booster COVID-19 vaccine doses in Canada [12-03-2021]
• Summary of NACI rapid response of December 3, 2021: guidance on booster COVID-19 vaccine doses in Canada [12-03-2021]
• NACI interim guidance on booster COVID-19 vaccine doses in Canada [10-29-2021]
• For immunization providers: Interim national vaccine storage, handling and transportation guidelines for ultra-low temperature and frozen temperature COVID-19 vaccines [09-22-2021]
• COVID-19 immunization: federal, provincial and territorial statement of common principles [modified 08-11-2021]
• Planning guidance for administration of COVID-19 vaccine [12-21-2020]
• Canada’s COVID-19 immunization plan: saving lives and livelihoods [no date]
• Recommendations on the duration of the post-vaccination observation period for influenza vaccination during the COVID-19 pandemic [10-14-2020]
• Interim guidance on continuity of immunization programs during the COVID-19 pandemic [05-13-2020]

Provinces and territories (other than Ontario)

• BC Pfizer Pediatric Vaccine Shipping, Storage, Thawing and Use Guidelines (Orange/Maroon cap) [09-22-2022]
• BC COVID-19 mRNA vaccine Comirnaty™ (Pfizer-BioNTech) [updated 10-11-2022]
• BC COVID-19 vaccine eligibility [updated 10-11-2022]
• Spikevax™ (Moderna) [updated 10-11-2022]
• BC Vaxzevria™/COVISHIELD (AstraZeneca/Verity Pharmaceuticals) [updated 09-14-2022]
• BC COVID-19 vaccine ChAdOx1-S [recombinant] [updated 09-14-2022]
• BC COVID-19 vaccine Nuvaxovid™ (Novavax) [updated 09-14-2022]
• BC COVID-19 vaccine Ad26.COV2.S [recombinant] (Janssen) [updated 09-08-2022]
• BC Guidance for receiving and handling the Pfizer-BioNTech COVID-19 mRNA vaccine (including dry ice procedures) [updated 10-11-2022]
• BC World Health Organization (WHO) emergency use authorization (EUA) qualified COVID-19 vaccines [updated 07-27-2022]
• BC Pfizer redistribution guidelines [updated 07-20-2022]
• BC Immunization manual appendix A: informed consent (page 4) [updated 07-20-2022]
• BC COVID-19 Pfizer vaccine shipping, storage, thawing and use guidelines [updated 07-20-2022]
• BC Moderna redistribution guidelines [updated 07-20-2022]
• BC Janssen shipping, storage and use guideline [updated 06-15-2022]
• BC Novavax shipping, storage and use guidelines [03-04-2022]
• Annexes to the interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222, SII Covishield, SK Bioscience) [03-15-2022]
• Annexes to the recommendations for use of the Sinovac-CoronaVac vaccine against COVID-19: grading of evidence, evidence to recommendation tables [03-15-2022]
• Interim recommendations for use of the ChAdOx1-S [recombinant] vaccine against COVID-19 (AstraZeneca COVID-19 vaccine AZD1222 Vaxzevria™, SII COVISHIELD™) [03-15-2022]
• Interim recommendations for use of the Moderna mRNA-1273 vaccine against COVID-19 [updated 02-23-2022]
• NVX-CoV2373 recombinant, adjuvanted COVID-19 vaccine [02-09-2022]
• COVAXIN® (BBV152) – Inactivated, COVID-19 vaccine [01-10-2022]
• Guidance on operational microplanning for COVID-19 vaccination [11-16-2021]
• Injection safety in the context of coronavirus disease (COVID-19) vaccination [11-05-2021]
• Annexes to WHO interim recommendations for use of the COVID-19 vaccine BIBP [10-28-2021]
• Coadministration of seasonal inactivated influenza and COVID-19 vaccines: interim guidance [10-21-2021]
• How to manage COVID-19 vaccines without VVM at vaccination service points? [08-31-2021]
• Training on handling, storing and transporting Pfizer BioNTech COVID-19 Vaccine COMIRNATY® (Tozinameran) [08-04-2021]
• Guidance on developing a national deployment and vaccination plan for COVID-19 vaccines [06-01-2021]
• Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19: [06-01-2021]
• Technical note on delayed shipments for the ChAdOx1-S [recombinant] vaccines: what are the implications for the administration of second doses?: Scientific brief [05-26-2021]
• Health worker communication for COVID-19 vaccination flow diagram [05-13-2021]
• AstraZeneca ChAdOx1-S/nCoV-19 [recombinant], COVID-19 vaccine: COVID-19 vaccine explainer [05-10-2021]
• AstraZeneca ChAdOx1-S [recombinant], COVID-19 vaccine [05-10-2021]
• Estimating COVID-19 vaccine effectiveness against severe acute respiratory infections (SARI) hospitalizations associated with laboratory-confirmed SARS-CoV-2: an evaluation using the test-negative design [05-07-2021]
• COVID-19 exercise programme - drills for vaccine deployment [05-03-2021]
• Why are there extra doses of vaccine in the vaccine vial? [04-16-2021]
• Data for action: achieving high uptake of COVID-19 vaccines: interim guidance [04-01-2021]
• Immunization as an essential health service: guiding principles for immunization activities during the COVID-19 pandemic and other times of severe disruption [11-01-2020]

CDC
• COVID-19 vaccine boosters [updated 10-24-2022]
• Stay up to date with your COVID-19 vaccines [updated 10-24-2022]
Interim infection prevention and control recommendations for healthcare personnel during the coronavirus disease 2019 (COVID-19) pandemic [updated 09-23-2022]

Understanding viral vector COVID-19 vaccines [updated 09-16-2022]

COVID-19 vaccination program operational guidance [updated 08-11-2022]

COVID-19 vaccine reporting systems [updated 07-19-2022]

COVID-19 vaccination clinical & professional resources [updated 05-13-2022]

Public health investigations of COVID-19 vaccine breakthrough cases: case investigations protocol [no date]

Interim guidance for routine and influenza immunization services during the COVID-19 pandemic [04-15-2021]

Expanding COVID-19 vaccine distribution to primary care providers to address disparities in immunization [04-14-2021]

UK

COVID-19 vaccination: information for healthcare practitioners [10-10-2022]

COVID-19 vaccination: vaccine product information [10-03-2022]

COVID-19 vaccination programme [updated 09-07-2022]


Monitoring reports of the effectiveness of COVID-19 vaccination [09-01-2022]

National protocol for COVID-19 Vaccine AstraZeneca (ChAdOx1-S [recombinant]) [04-01-2022]

National protocol for Comirnaty® 30microgram/dose COVID-19 mRNA vaccine [04-01-2022]

National protocol for Spikevax (formerly COVID-19 vaccine Moderna) [04-01-2022]

COVID-19 vaccination: blood clotting information for healthcare professionals [updated 02-14-2022]

COVID-19 vaccination: booster dose resources [updated 02-02-2022]

National protocol for COVID-19 mRNA vaccine BNT162b2 (Pfizer/BioNTech) [11-20-2021]

COVID-19 vaccination: what to expect after vaccination [updated 11-09-2021]

Monitoring of the effectiveness of COVID-19 vaccination [09-14-2021]

COVID-19: vaccine surveillance strategy [03-29-2021]

ECDC

Overview of the implementation of COVID-19 vaccination strategies and vaccine deployment plans in the EU/EEA, [updated 09-08-2022]

COVID-19: recommendations for those vaccinated with vaccines not authorized by Health Canada for those staying in Canada to live, work or study [modified 08-05-2022]

Updated joint statement from ECDC and EMA on additional booster doses of COVID-19 vaccines [07-11-2022]

Public health considerations and evidence to support decisions on the implementation of a second mRNA COVID-19 vaccine booster dose [04-28-2022]

Interim analysis of COVID-19 vaccine effectiveness against severe acute respiratory infection due to laboratory-confirmed SARS-CoV-2 among individuals aged 30 years and older, ECDC multi-country study – second update [03-14-2022]
- **Generic protocol for COVID-19 vaccine effectiveness studies during outbreaks in semi-closed settings in the EU/EEA** [12-14-2021]
- **Facilitating COVID-19 vaccination acceptance and uptake in the EU/EEA** [10-15-2021]
- **Infographic: facilitating COVID-19 vaccination acceptance and uptake** [10-15-2021]
- **Core protocol for ECDC studies of COVID-19 vaccine effectiveness against hospitalisation with severe acute respiratory infection laboratory-confirmed with SARS-CoV-2, version 1.0** [10-08-2021]
- **Interim public health considerations for the provision of additional COVID-19 vaccine doses** [09-01-2021]
- **Partial COVID-19 vaccination, vaccination following SARS-CoV-2 infection and heterologous vaccination schedule: summary of evidence** [07-22-2021]
- **Countering online vaccine misinformation in the EU/EEA** [06-29-2021]

**Australia**
- **Clinical recommendations for COVID-19 vaccines** [updated 10/24/2022]
- **ATAGI recommendations on the use of a booster dose of COVID-19 vaccine** [updated 10/24/2022]
- **ATAGI clinical guidance for COVID-19 vaccine providers** [updated 09-28-2022]
- **COVID-19 vaccination – ATAGI guidance on the use of multi-dose vials for COVID-19 vaccination** [08-31-2022]
- **COVID-19 vaccination – vaccine dose policy** [updated 07-13-2022]
- **COVID-19 vaccination – updated provider kit for general practices** [12-14-2021]

**Vaccinations- Specific populations**

**Canada (Federal)**
- **An Advisory CommitteeStatement (ACS) National Advisory Committee on Immunization (NACI) Recommendations on the use of Pfizer-BioNTechComirnaty (3 mcg) COVID-19 vaccine in children 6 months to 4 years of age** [10-21-2022]
- **Updated guidance on COVID-19 vaccines for individuals who are pregnant or breastfeeding** [09-09-2022]
- **Quick reference guide on use of COVID-19 vaccines for children 5 to 11 years of age: overview** [modified 08-11-2022]
- **Recommendations on the use of Moderna Spikevax COVID-19 vaccine in children 6 months to 5 years of age** [07-14-2022]
- **Summary of NACI statement of July 14, 2022** [07-14-2022]
- **NACI rapid response: guidance on the use of booster COVID-19 vaccine doses in adolescents 12 to 17 years of age** [archived] [modified 06-29-2022]
- **NACI rapid response: updated guidance on COVID-19 vaccination timing for individuals previously infected with SARS-CoV-2** [archived] [modified 06-29-2022]
• **NACI updated recommendations on the use of COVID-19 vaccines in children 5 to 11 years of age** [archived] [modified 03-17-2022]

• **Planning for the 2021-2022 school year in the context of COVID-19 vaccination** [modified 02-10-2022]

• ** Archived: National Advisory Committee on Immunization (NACI) statement: recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine (10 mcg) in children 5 to 11 years of age** [updated 01-25-2022]

• **NACI rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines** [12-03-2021]

• **Summary of NACI rapid response of December 3, 2021: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines** [12-03-2021]

Provinces and territories (other than Ontario)

• **BC**  [COVID-19 mRNA vaccine Comirnaty™ (Pfizer-BioNTech) adult/adolescent** [updated 10-11-2022]

• **BC Health professionals COVID-19 vaccination status information and preventive measures – June 10, 2022** [06-10-2022]

• **BC Residential care COVID-19 vaccination status** [02-28-2022]

WHO

• **Interim recommendations for an extended primary series with an additional vaccine dose for COVID-19 vaccination in immunocompromised persons** [10-26-2021]

• **Update on WHO Interim recommendations on COVID-19 vaccination of pregnant and lactating women** [06-10-2021]

• **Disability considerations for COVID-19 vaccination: WHO and UNICEF policy brief, 19 April 2021** [04-26-2021]

CDC

• **COVID-19 vaccines for children and teens** [updated 10-24-2022]

• **COVID-19 vaccines while pregnant or breastfeeding** [updated 10-20-2022]

• **COVID-19 vaccines for people who would like to have a baby** [updated 07-14-2022]

• **Resources to promote the COVID-19 vaccine for children & teens** [09-13-2022]

• **COVID-19 vaccine information for specific groups** [06-19-2022]

• **COVID-19 vaccine equity for racial and ethnic minority groups** [03-29-2022]

• **Guidance for vaccinating older adults and people with disabilities: ensuring equitable covid-19 vaccine access** [01-20-2022]

• **Guidance for vaccinating older adults and people with disabilities at vaccination sites** [08-10-2021]

• **Interim guidance for health departments: COVID-19 vaccination implementation for people experiencing homelessness** [04-30-2021]

UK
• **COVID-19 vaccination: women of childbearing age, currently pregnant or breastfeeding** [10-03-2022]
• **COVID-19 vaccination: resources for children aged 5 to 11 years** [03-28-2022]
• **COVID-19 vaccination: resources for children and young people aged 12 to 17 years** [02-01-2022]
• **COVID-19 vaccination: guide for adults** [01-19-2022]
• **Interim public health considerations for COVID-19 vaccination of children aged 5-11 years** [12-01-2021]
• **Safety of COVID-19 vaccines when given in pregnancy** [04-30-2021]

**ECDC**

• **Data collection on COVID-19 outbreaks in closed settings: long-term care facilities, version 2.1** [02-18-2022]
• **COVID-19 vaccine effectiveness in adolescents aged 12–17 years and interim public health considerations for administration of a booster dose** [02-08-2022]
• **Interim public health considerations for COVID-19 vaccination of adolescents in the EU/EEA** [06-01-2021]

**Vaccinations - Adverse Effects**

**Canada (Federal)**

• **National Advisory Committee on Immunization (NACI): rapid response: updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccines** [12-03-2021]
• **Reports of myocarditis and pericarditis after COVID-19 vaccination: communiqué to health practitioners (June 3, 2021)** [06-14-2021]

**Provinces and territories (other than Ontario)**

• **BC Guidance document on the management of inadvertent vaccine errors** [02-04-2022]
• **BC Myocarditis/pericarditis in association with receipt of mRNA COVID-19 vaccine** [06-11-2021]
• **BC COVID-19 vaccine planning guide for people who are pregnant or breastfeeding** [10-12-2021]
• **BC Summary of AEFI reporting criteria for COVID-19 vaccination for older children, adolescents and adults** [no date]

**CDC**

• **Reported Adverse Events** [updated 10-17-2022]
• **COVID-19 vaccine side effects in children and teens** [updated 09-14-2022]
• **Possible side effects after getting a COVID-19 vaccine** [updated 09-14-2022]
• **Interim considerations: preparing for the potential management of anaphylaxis after COVID-19 vaccination** [updated 09-02-2022]
• Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination [08-09-2021]

WHO
• How to manage COVID-19 vaccines without VVM at vaccination service points? [08-31-2021]
• COVID-19 vaccines: safety surveillance manual. Module on safety surveillance of COVID-19 vaccines in pregnant and breastfeeding women [07-12-2021]
• How to monitor and report COVID-19 vaccine side effects [03-15-2021]

UK
• COVID-19 vaccination: myocarditis and pericarditis information for healthcare professionals [updated 10-07-2022]
• COVID-19 vaccination: myocarditis and pericarditis information for healthcare professionals [03-21-2022]
• Myocarditis and pericarditis after COVID-19 vaccination [03-21-2022]
• COVID-19 vaccination: Guillain-Barré syndrome information for healthcare professionals [12-17-2021]
• Safety of COVID-19 vaccines when given in pregnancy [04-30-2021]

Australia
• COVID-19 vaccination – guidance on myocarditis and pericarditis after mRNA COVID-19 vaccines [09-23-2022]
• ATAGI clinical guidance on COVID-19 vaccine administration errors [09-07-2022]
• COVID-19 vaccination – primary care approach to thrombosis with thrombocytopenia syndrome after COVID-19 AstraZeneca vaccine [03-01-2022]

Background Information/Case Definitions
Ontario Ministry of Health
• Ontario case definition - coronavirus disease (COVID-19) [06-00-2022]

PHAC
• National case definition: coronavirus disease (COVID-19) [updated 10-03-2022]
• COVID-19 case report form [updated 09-09-2022]

CDC
• Coronavirus disease 2019 (COVID-19) 2020 interim case definition, approved August 5, 2020 [04-16-2021]

WHO
• WHO COVID-19 Case definition [updated 07-22-2022]
• Revised case report form for confirmed Novel Coronavirus COVID-19 (report to WHO within 48 hours of case identification) [updated 07-22-2022]
• A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 [10-06-2021]

ECDC
- Reinfection with SARS-CoV-2: implementation of a surveillance case definition within the EU/EEA [04-08-2021]

UK
- COVID-19: epidemiology, virology and clinical features [05-17-2022]
- COVID-19: background information [05-17-2022]

Australia
- COVID-19 disease, symptoms and variants [updated 10-14-2022]

Other
- BMJ best practice COVID-19 [updated regularly]

Laboratories

Ontario Ministry of Health
- Management of cases and contacts of COVID-19 in Ontario (version 15) [updated 08-31-2022]

PHAC
- Biosafety advisory: SARS-CoV-2 (severe acute respiratory syndrome-related coronavirus 2) [07-05-2022]
- Requirements for serological antibody tests submitted under the COVID-19 interim order: guidance [04-12-2022]
- Polymerase chain reaction (PCR) and cycle threshold (Ct) values in COVID-19 testing [06-10-2021]
- National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [10-07-2020]

WHO
- Operational considerations to expedite genomic sequencing component of GISRS surveillance of SARS-CoV-2 [03-30-2021]
- Acknowledgements: the Unity Studies for sero-epidemiological investigation of COVID-19 [03-24-2022]
- Laboratory biosafety guidance related to coronavirus disease (COVID-19) [01-28-2021]
- COVID-19 new variants: knowledge gaps and research [01-12-2021]
- Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health [01-08-2021]
- SARS-CoV-2 genomic sequencing for public health goals [01-08-2021]
- SARS-CoV-2 antigen-detecting rapid diagnostic tests: an implementation guide [12-21-2020]
- Assessment tool for laboratories implementing SARS-CoV-2 testing [10-23-2020]
- Diagnostic testing for SARS-CoV-2: interim guidance [09-11-2020]
- Antigen-detection in the diagnosis of SARS-CoV-2 infection using rapid immunoassays [09-11-2020]
CDC

- **Interim guidelines for collecting, handling, and testing clinical specimens for COVID-19** [updated 07-17-2022]
- **Testing strategies for SARS-CoV-2** [05-05-2022]
- **How to report COVID-19 laboratory data** [04-04-2022]
- **Guidance for SARS-CoV-2 point-of-care and rapid testing** [04-04-2022]
- **Guidance for reporting SARS-CoV-2 sequencing results** [03-21-2022]
- **Evaluation for SARS-CoV-2 testing in animals** [03-30-2022]
- **Guidance for general laboratory safety practices during the COVID-19 pandemic** [03-02-2022]
- **Using antibody tests for COVID-19** [02-24-2022]
- **Interim guidelines for COVID-19 antibody testing: interim guidelines for COVID-19 antibody testing in clinical and public health settings** [01-24-2022]
- **Interim laboratory biosafety guidelines for handling and processing specimens associated with coronavirus disease 2019 (COVID-19)** [12-13-2021]
- **Science brief: SARS-CoV-2 infection-induced and vaccine-induced immunity** [10-29-2021]
- **Lab tests to collect shortly after severe allergic reaction/anaphylaxis following COVID-19 vaccination** [08-09-2021]
- **Interim guidance for use of pooling procedures in SARS-CoV-2 diagnostic and screening testing** [06-30-2021]
- **Variants and genomic surveillance for SARS-CoV-2** [04-02-2021]
- **Resources for laboratories working on coronavirus (COVID-19)** [03-28-2021]
- **Information for laboratories about coronavirus (COVID-19)** [03-28-2021]

UK

- **How tests and testing kits for coronavirus (COVID-19) work** [10-07-2022]
- **Outcome of the evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices)** [07-11-2022]
- **National standardised test performance process for manufacturers of SARS-CoV-2 virus antibody tests** [07-11-2022]
- **Protocol for evaluation of rapid diagnostic assays for specific SARS-CoV-2 antigens (lateral flow devices)** [07-11-2022]
- **Technical validation protocol for SARS-CoV-2 nucleic acid detection** [07-11-2022]
- **NHS test and trace statistics (England): methodology** [05-18-2022]
- **COVID-19: guidance for sampling and for diagnostic laboratories** [03-29-2021]

ECDC

- **The use of antibody tests for SARS-COV-2 in the context of Digital Green Certificates** [05-10-2021]

Australia

- **PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19)** [01-28-2022]
Miscellaneous Guidelines

**PHAC**
- Summary of evidence supporting COVID-19 public health measures [08-31-2022]
- Individual public health measures [updated 08-12-2022]
- COVID-19 and people with disabilities in Canada [07-06-2022]
- Federal/provincial/territorial public health response plan for ongoing management of COVID-19 [04-08-2022]

**Canadian provinces and territories (other than Ontario)**
- BC COVID-19 ethical decision-making framework [12-24-2020]

**WHO**
- Summary: Consolidated financing framework for ACT-accelerator agency and in-country needs [02-16-2022]
- Consolidated financing framework for ACT-A agency & in-country needs [02-09-2022]
- ACT-Accelerator 'fair share asks' - by country [02-09-2022]
- WHO technical consultation on oxygen access scale-up for COVID-19 [07-14-2021]
- Modelling the health impacts of disruptions to essential health services during COVID-19: Module 1: Understanding modelling approaches for sexual, reproductive, maternal, newborn, child and adolescent health, and nutrition [07-09-2021]
- Considerations in adjusting public health and social measures in the context of COVID-19: interim guidance [06-14-2021]

**CDC**
- Return to work criteria for healthcare personnel with SARS-CoV-2 infection (interim guidance) [09-23-2022]
- Public health guidance for potential COVID-19 exposure associated with travel [updated 09-08-2022]
- Wildfire smoke and COVID-19 [08-02-2022]
- RRT composition: COVID-19 considerations [03-01-2021]

**ECDC**
- One-day in-action review (IAR) protocol in the context of COVID-19 [03-00-2021]
- Behavioural Insights research to support the response to COVID-19: a survey of implementation in the EU/EEA [02-17-2021]

**Other**
- Public health ethics and COVID-19: selected resources – National Collaborating Centre for Healthy Public Policy [11-30-2021]
Data & Surveillance

Canada
- COVID-19 data trends [modified 10-21-2022]
- Mathematical modelling and COVID-19 [modified 04-01-2022]
- National surveillance guidelines for coronavirus disease (COVID-19) [03-19-2021]

WHO
- Environmental surveillance for SARS-COV-2 to complement public health surveillance – Interim Guidance [04-14-2022]
- WHO COVID-19 essential supplies forecasting tool (COVID-ESFT) [02-15-2022]
- End-to-end integration of SARS-CoV-2 and influenza sentinel surveillance: revised interim guidance [01-31-2022]
- Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for Member States [01-21-2022]

CDC
- Wastewater surveillance data reporting & analytics [updated 10-04-2022]
- National wastewater surveillance system (NWSS) [03-21-2022]
- Wastewater surveillance testing methods [01-26-2022]
- Public health interpretation and use of wastewater surveillance data [01-26-2022]
- Developing a wastewater surveillance sampling strategy [01-26-2022]
- Targeted wastewater surveillance at facilities, institutions, and workplaces [01-26-2022]
- COVID-19 serology surveillance [03-11-2021]
- Data visualization [02-16-2021]
- Large-scale geographic seroprevalence surveys [10-02-2020]

ECDC
- Organisation of vector surveillance and control in Europe [12-13-2021]
- Surveillance of COVID-19 in long-term care facilities in the EU/EEA [11-29-2021]
- Epidemiological update: Omicron variant of concern (VOC) – data as of 29 November 2021 (12:30) [11-29-2021]
- COVID-19 variants: genomically confirmed case numbers [11-29-2021]
- Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA [11-26-2021]
- COVID-19 surveillance guidance - transition from COVID-19 emergency surveillance to routine surveillance of respiratory pathogens [10-18-2021]
- Guidance for representative and targeted genomic SARS-CoV-2 monitoring [05-03-2021]

UK
- COVID-19 surveillance in school KIDs (sKIDs): pre and primary schools [09-04-2020]
Variants – Omicron

Canada
- SARS-CoV-2 variants: national definitions, classifications and public health actions [updated 08-18-2022]

CDC
- Variants [updated 08-11-2021]

UK
- Investigation of SARS-CoV-2 variants: technical briefings [updated 10-07-2022]
- SARS-CoV-2 variants of public health interest [updated 10-07-2022]

ECDC
- Methods for the detection and characterisation of SARS-CoV-2 variants – first update [updated 08-02-2022]
- Implications of the emergence and spread of the SARS-CoV-2 variants of concern BA.4 and BA.5 for the EU/EEA [06-13-2022]
- Technical guidance for antigenic SARS-CoV-2 monitoring [06-07-2022]
- Assessment of the further emergence of the SARS-CoV-2 Omicron VOC in the EU/EEA, 19th update [01-27-2022]
- Threat assessment brief: implications of the further emergence and spread of the SARS-CoV 2 B.1.1.529 variant of concern (Omicron) fo the EU/EEA first update [12-02-2021]
- Epidemiological update: Omicron variant of concern (VOC) – data as of 30 November 2021 (12.00) [11-30-2021]
- Threat assessment brief: implications of the emergence and spread of the SARS-CoV-2 B.1.1.529 variant of concern (Omicron) for the EU/EEA [11-26-2021]

WHO
- Enhancing readiness for Omicron (B.1.1.529): technical brief and priority actions for member stats [updated 01-21-2022]

Testing

Canada
- Interim guidance on the use of rapid antigen detection tests for the identification of SARS-CoV-2 infection [07-07-2022]
- Pan-Canadian COVID-19 testing and screening guidance: technical guidance and implementation plan [09-08-2021]
- Guidance for repeated PCR testing in individuals previously positive for COVID-19 [12-08-2020]
- National polymerase chain reaction (PCR) testing indication guidance for COVID-19 [10-07-2020]

Ontario Ministry of Health
- COVID-19 test requisition [06-12-2021]
- Considerations for privately-initiated testing, version 3.0 [05-21-2021]
- COVID-19 guidance: considerations for rapid antigen screening. Version 2.0 [02-17-2021]
- Considerations for employer rapid antigen screening pilot [11-20-2020]

Canadian provinces and territories (other than Ontario)
- BC Infection prevention and control guidance for test collection and assessment centres [09-09-2021]
- BC Antibody testing (serology) page [no date]

WHO
- Use of SARS-CoV-2 antigen-detection rapid diagnostic tests for COVID-19 self-testing [03-09-2022]

CDC
- Overview of testing for SARS-CoV-2 (COVID-19) [updated 09-28-2022]
- Testing strategies for SARS-CoV-2 [05-05-2022]
- Guidance for antigen testing for SARS-CoV-2 for healthcare providers testing individuals in the community [04-04-2022]
- Guidance for SARS-CoV-2 point-of-care and rapid testing [04-04-2022]
- Using antibody tests for COVID-19 [02-24-2022]
- CDC’s diagnostic test for COVID-19 only and supplies [08-17-2021]
- CDC diagnostic tests for covid-19 [08-07-2021]
- Nucleic acid amplification tests (NAATs) [06-14-2021]
- Guidance for healthcare workers about COVID-19 (SARS-CoV-2) testing [06-14-2021]
- Performing broad-based testing for SARS-CoV-2 in congregate correctional, detention, and homeless service settings [03-29-2021]
- Serology testing for COVID-19 at CDC [11-03-2020]

UK
- Investigation of SARS-CoV-2 variants: technical briefings [updated 07-16-2021]
- How tests and testing kits for coronavirus (COVID-19) work [updated 07-16-2021]
- SARS-CoV-2 variants of public health interest [updated 07-16-2021]
- Investigation of SARS-CoV-2 variants of concern: variant risk assessments [06-24-2022]
- SARS-CoV-2 variant of concern diagnostic assurance [04-14-2022]
- Testing for coronavirus (COVID-19) before hospital [03-08-2022]
- Coronavirus COVID-19 serology and viral detection tests: technical validation reports [updated 02-18-2022]
- Investigation of SARS-CoV-2 variants of concern: technical briefings [09-17-2021]
- Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Delta, 8 July 2021 [07-16-2021]
- Investigation of SARS-CoV-2 variants of concern – variant risk assessments for SARS-CoV-2 variant, Lambda, 8 July 2021 [07-16-2021]
• **SARS-CoV-2 RNA testing: assurance of positive results during periods of low prevalence** [10-16-2020]

**ECDC**

• **Methods for the detection and identification of SARS-CoV-2 variants- first update** [08-02-2022]
• **A scoping review of point-of-care testing devices for infectious disease surveillance, prevention and control** [04-27-2022]
• **Assessment of point-of-care testing devices for infectious disease surveillance, prevention and control – a mapping exercise** [04-27-2022]
• **Considerations for the use of antibody tests for SARS-CoV-2 – first update** [02-10-2022]
• **Rapid assessment of antigenic characterisation capability and capacity for SARS-CoV-2 viruses in EU/EEA laboratories** [12-20-2021]
• **Options for the use of rapid antigen tests for COVID-19 in the EU/EEA and the UK** [10-26-2021]
• **Considerations on the use of rapid antigen detection (including self-) tests for SARS-CoV-2 in occupational settings** [05-06-2021]
• **Considerations for the use of saliva as sample material for COVID-19 testing** [05-03-2021]
• **Considerations on the use of self-tests for COVID-19 in the EU/EEA** [03-17-2021]
• **Guidance for COVID-19 quarantine and testing of travellers** [03-12-2021]
• **Detection and characterisation capability and capacity for SARS-CoV-2 variants within the EU/EEA** [02-16-2021]
• **Risk assessment: SARS-CoV-2 - increased circulation of variants of concern and vaccine rollout in the EU/EEA, 14th update** [02-15-2021]
• **COVID-19 testing strategies and objectives** [09-18-2020]
• **Objectives for COVID-19 testing in school settings** [08-10-2020]

**Australia**

• **PHLN and DCNA joint statement on SARS-CoV-2 rapid antigen tests** [06-20-2022]
• **PHLN guidance on laboratory testing for SARS-CoV-2 (the virus that causes COVID-19)** [01-28-2022]

**Symptoms/Treatment**

**Canada**

• **COVID-19 signs, symptoms and severity of disease: a clinician guide** [06-01-2022]
• **Considerations for the use of nirmatrelvir/ritonavir to treat COVID-19 in the context of limited supply** [06-22-2022]
• **COVID-19 for health professionals: treatments** [02-01-2022]
• **Non-contact infrared thermometers (NCIT)** [01-28-2021]

**Ontario Ministry of Health**

Management of cases and and contacts of COVID-19 in Ontario version 15 [updated 08-31-2022]

• **Guidance for employers managing workers with symptoms within 48 hours of COVID-19 immunization. Version 3** [11-30-2021]
• **COVID-19 patient screening guidance document version 5.0** [08-26-2021]
BC
- Clinical Practice Guide for the Use of Therapeutics in Mild-Moderate COVID-19 [updated 10-14-2022]
- Therapy in adult pregnant patients with COVID-19 [updated 09-07-2022]

WHO
- COVID-19 disease in children and adolescents: scientific brief, 29 September 2021 [09-29-2021]
- Neurology and COVID-19: scientific brief, 29 September 2021 [09-29-2021]
- WHO living guideline: drugs to prevent COVID-19 [03-02-2021]
- Home care for patients with COVID-19 presenting with mild symptoms and management of their contacts: interim guidance [08-12-2020]

CDC
- Clinical Care Information for COVID-19 [updated 10-19-2022]
- Caring for post-COVID conditions [updated 09-01-2022]
- Ending home isolation for persons with COVID-19 not in healthcare settings [08-31-2022]
- Ending isolation and precautions for people with COVID-19: interim guidance [08-31-2022]
- If you are sick or caring for someone [08-11-2022]
- Underlying medical conditions associated with higher risk for severe COVID-19: information for healthcare providers [06-15-2022]
- Clinical care quick reference for COVID-19 [03-16-2022]
- Care for breastfeeding people: interim guidance on breastfeeding and breast milk feeds in the context of covid-19 [02-25-2022]

WHO
- Therapeutics and COVID-19 [07-14-2022]
- COVID-19 clinical care pathway (CARE): confirm, assess, respond, evaluate [02-04-2022]
- COVID-19 clinical care pathway (CARE): confirm SARS-CoV-2 infection, assess symptoms, risk factors and severity, respond with appropriate care and treatment, evaluate clinical response and recovery [02-04-2022]
• **COVID-19 clinical management: living guidance** [11-23-2021]
• **Clinical features and prognostic factors of COVID-19 in people living with HIV hospitalized with suspected or confirmed SARS-CoV-2 infection** [07-15-2021]
• **Hypertension and COVID-19** [06-17-2021]
• **WHO information note: COVID-19 considerations for tuberculosis (TB) care** [05-05-2021]
• **Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021** [04-24-2021]
• **WHO COVID-19 clinical care bundle** [04-23-2021]
• **Home care for patients with suspected or confirmed COVID-19 and management of their contacts: interim guidance** [08-13-2020]

**US NIH**

• **COVID-19 treatment guidelines** [updated 10-19-2022]

**UK**

• **COVID-19: migrant health guide** [03-08-2022]
• **COVID-19: long-term health effects** [updated 04-30-2021]

**Australia**

• **Coronavirus (COVID-19) – identifying the symptoms** [last updated 07-05-2022]

**COVID-19 Diagnosis in Children**

**Canada**


**WHO**

• **COVID-19 disease in children and adolescents: Scientific brief, 29 September 2021** [09-29-2021]

**CDC**

• **Information for Pediatric Healthcare Providers** [10-19-2022]
• **Information for healthcare providers about multisystem inflammatory syndrome in children (MIS-C)** [05-20-2021]

**Other**

• **BC Children with immune compromise** [08-02-2022]
• **American Academy of Pediatrics What is the case definition of multisystem inflammatory syndrome in children (MIS-C) interim guidance** [06-10-2022]
• **BC Pediatric clinical guidance for COVID-19** [09-27-2021]
• **BC Multisystem inflammatory syndrome in children (MIS-C) temporally associated with COVID-19: guidance for clinicians in B.C.** [07-05-2021]
• **BC Guidance for newborn care, resuscitation procedures and lactation** [06-11-2021]
• **BC Management of severe respiratory illness in pediatric patients during the COVID-19 pandemic** [05-12-2021]
Post-COVID-19 Condition

Canada
- Post COVID-19 condition (long COVID) [updated 10-20-2022]

Ontario
- Ontario Health Post COVID-19 condition: guidance for primary care [12-00-2021]
- BC Living with persistent Post-COVID-19 symptoms
- Science Table Understanding the post COVID-19 condition (long COVID) and the expected burden for Ontario [09-14-2021]

WHO
- Evaluating and caring for patients with post-COVID conditions: interim guidance [updated 10-22-2021]
- Expanding our understanding of post COVID-19 condition: report of a WHO webinar - 9 February 2021 [04-24-2021]

CDC
- Post-COVID conditions: information for healthcare providers [updated 09-22-2021]
- Post-COVID conditions; CDC Science [09-02-2022]
- Caring for post-COVID conditions [09-01-2022]
- Evaluating and caring for patients with post-COVID conditions: interim guidance [06-14-2021]

UK
- Long-term effects of coronavirus (long COVID) [08-09-2022]

Case Investigation & Contact Tracing

Canada
- Public health management of cases and contacts associated with COVID-19 [08-18-2022]

Ontario
- Management of cases and contacts of COVID-19 in Ontario (version 15) [08-31-2022]

WHO
- Contact tracing and quarantine in the context of the Omicron SARS-CoV-2 variant: interim guidance [02-17-2022]

CDC
- Ending home isolation for persons with COVID-19 not in healthcare settings [08-31-2022]
- Quarantine and isolation [08-11-2022]
- Contact tracing resources for health departments [03-25-2022]
- Contact tracer's interview tool: notifying people about an exposure to COVID-19 [02-28-2022]
- Interim guidance on developing a covid-19 case investigation & contact tracing plan: overview [02-28-2022]
- Prioritizing case investigations and contact tracing for covid-19 in high burden jurisdictions [02-28-2022]
- Contact tracing for COVID-19 [02-10-2022]
- Investigating a COVID-19 case [01-21-2022]
Infection Prevention and Control

PHAC / Health Canada

- Coronavirus disease (COVID-19): prevention and risks [08-12-2022]
- COVID-19: Guidance on indoor ventilation during the pandemic [07-05-2022]
- Federal/provincial/territorial public health response plan for ongoing management of COVID-19 [04-08-2022]
- Update with consideration of Omicron – interim COVID-19 infection prevention and control in the health care setting when COVID-19 is suspected or confirmed—December 23, 2021 [12-24-2021]
- At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [12-15-2021]

Ontario

- COVID-19 guidance: personal protective equipment (PPE) for health care workers and health care entities version 1.0 [06-10-2022]

Canadian provinces and territories (other than Ontario)

- BC COVID-19: outbreak management protocol for acute care settings [02-02-2022]

WHO

- Roadmap to improve and ensure good indoor ventilation in the context of COVID-19 [03-01-2021]

CDC

• Considerations for inpatient obstetric healthcare settings [11-19-2021]
• Cleaning and disinfecting your facility: every day and when someone is sick [11-15-2021]

UK
• Ventilation of indoor spaces to stop the spread of coronavirus (COVID-19) [08-02-2022]
• Technical specifications for personal protective equipment (PPE) [02-14-2022]

Other
• BC Infection prevention and control guidance for community immunization clinics [09-28-2022]
• BC The hierarchy for infection prevention and exposure control measures for communicable diseases [06-29-2022]

Section II: Guidelines for Health Sectors
Healthcare Providers
Ontario Ministry of Health
• Management of cases and and contacts of COVID-19 in Ontario version 15 [08-31-2022]
• COVID-19 guidance: acute care v.8 [06-11-2022]
• COVID-19 guidance: personal protective equipment (PPE) for health care workers and health care entities version 1.0 [06-10-2022]
• COVID-19 guidance: independent health facilities: version 4 [06-19-2020]

Canada
• COVID-19 pandemic guidance for the health care sector: 4.3 human resources [04-22-2020]

WHO
• COVID-19 home care bundle for health care workers [02-09-2022]
• Global pulse survey on continuity of essential health services during the COVID-19 pandemic [02-07-2022]
• Third round of the global pulse survey on continuity of essential health services during the COVID-19 pandemic [02-07-2022]

CDC
• Interim guidance for managing healthcare personnel with SARS-CoV-2 infection or exposure to SARS-cov-2 [09-23-2022]
• Staff shortages [09-23-2022]
• Operational considerations for the identification of healthcare workers and inpatients with suspected COVID-19 in non-U.S. healthcare settings [01-14-2022]

UK
• COVID-19: managing healthcare staff with symptoms of a respiratory infection [08-31-2022]
Congregate Living (including Long-Term Care, Prisons, and Shelters)

Ontario Ministry of Health

- COVID-19 screening tool for long-term care homes and retirement homes: version 13 [08-31-2022]
- Ministry for seniors and accessibility COVID-19 guidance document for retirement homes in Ontario [06-24-2022]

PHAC

- COVID-19: guidance on pets and long-term care homes [07-20-2021]
- Using ventilation and filtration to reduce aerosol transmission of COVID-19 in long-term care homes [04-12-2021]
- COVID-19 guidance for long-term care facilities and nursing homes in Indigenous communities [04-14-2020]

WHO

- Infection prevention and control guidance for long-term care facilities in the context of COVID-19 update: interim guidance [01-08-2021]

CDC

- How to protect yourself and others [updated 10-19-2022]
- Interim infection prevention and control recommendations for healthcare personnel during the Coronavirus disease 2019 (COVID-19) pandemic [09-23-2022]
- Correctional and detention facilities [06-10-2022]
- Guidance on prevention and management of COVID-19 in correctional and detention facilities [05-03-2022]
- Interim guidance for SARS-CoV-2 testing in homeless shelters and encampments [04-06-2022]
- Investigating cases in homeless shelters [02-10-2022]
- Interim guidance on people experiencing unsheltered homelessness [02-10-2022]
- Interim guidance for homeless service providers to plan and respond to Coronavirus Disease 2019 (COVID-19) [02-10-2022]
- Interim guidance for general population disaster shelters during the COVID-19 pandemic [08-30-2021]

UK

- Covid-19 testing in homelessness, domestic abuse refuse and respite room settings [updated 08-31-2022]
- Operating principles for night shelters [08-31-2022]
• Preventing and controlling outbreaks of COVID-19 in prisons and places of detention [07-27-2022]
• Flu and acute respiratory illness in prisons and secure settings: information for staff [04-06-2022]
• Visiting someone in prison [04-01-2022]
• Data collection on COVID-19 outbreaks in closed settings with a completed vaccination programme: long-term care facilities, v. 2.1 [02-18-2022]
• Infection control in prisons and places of detention [07-01-2011]

Other
• CSC Testing of inmates in federal correctional institutions for COVID-19 [07-08-2022]

Section III: Guidelines for the Community
Travel, Transport & Borders

Ontario Ministry of Health
• Travelling during COVID-19 [07-19-2022]
• Guidance for public transit agencies and passengers in response to COVID-19 [03-21-2022]

Canada
• Official global travel advisories [updated often]
• COVID-19: travel, testing, quarantine and borders [10-19-2022]

CDC
• COVID-19 travel recommendations by destination [updated regularly]
• Stay up to date with your COVID-19 vaccines including Boosters [updated 10-24-2022]
• Requirement for proof of COVID-19 vaccination for air passengers [07-14-2022]

UK
• COVID-19: guidance for people whose immune system means they are at higher risk [updated 10-07-2022]
• People with symptoms of a respiratory infection including COVID-19 [06-10-2022]
• Coronavirus (COVID-19): advice for heavy goods (HGV) and public service vehicle (PSV) operators [03-29-2022]
• Coronavirus (COVID-19): cruise ship travel [03-17-2022]

Schools / Childcare

Ontario Ministry of Health
• Management of cases and contacts of COVID-19 in Ontario version 15 [08-31-2022]
• COVID-19: health and safety measures for child care [08-17-2022]
• COVID-19: health and safety measures at schools [08-15-2022]

PHAC
• Evaluating COVID-19 disease transmission and public health measures in schools: outbreak investigation guidance [07-22-2022]
• Planning for the 2021-2022 school year in the context of COVID-19 vaccination [02-10-2022]
**CDC**
- Guidance for K-12 schools and childcare programs [08-11-2022]
- Schools, child care, and colleges [08-11-2022]

**UK**
- Emergency planning and response for education, childcare, and children's social care settings [updated 10-03-2022]

---

**Mental Health /Addiction**

**Ontario Ministry of Health**

**Provinces & Territories (excluding Ontario)**
- QC The roles of public health in population mental health and wellness promotion [10-03-22]
- QC Housing and social inequalities in health in times of COVID-19: strategies for promoting affordable quality housing [04-05-2022]
- QC Preventing violence and suicide within the context of the COVID-19 pandemic: courses of action [04-05-2022]
- QC Preventing loneliness in young adults in the context of a pandemic [04-05-2022]
- BC Impacts of the COVID-19 pandemic on the health and wellbeing of young adults in British Columbia [07-00-2021]
- QC Public health ethics and COVID-19: selected resources [11-00-2021]

**WHO**
- Mental health and COVID-19: early evidence of the pandemic’s impact: scientific brief, 2 March 2022 [03-02-2022]
- Rise, respond, recover: renewing progress on women’s, children’s and adolescent’s health in the era of COVID-19 [12-00-2021]
- Social isolation and loneliness among older people: advocacy brief [07-29-2021]
- Smoking and COVID-19 [06-30-2020]
- Addressing violence against children, women and older people during the COVID-19 pandemic: key actions [06-18-2020]
- COVID-19 and violence against women: what the health sector / system can do [04-07-2020]

**SAMHSA**
- Disaster planning handbook for behavioural health service programs [03-00-2021]
- Considerations for the care and treatment of mental and substance use disorders in the COVID-19 epidemic: March 20, 2020 [05-07-2020]
- Intimate partner violence and child abuse considerations during COVID-19 [no date]

---

**Back to Top**
- Alcohol and drug misuse prevention and treatment guidance [03-07-2022]
- Every Mind Matters: looking after your mental health [no date]
- Domestic abuse: how to get help [11-11-2021]

Community

Ontario Ministry of Health
- COVID-19 public health measures and advice [updated 10-12-2022]
- COVID-19 guidance: community emergency evacuations v.3 [05-16-2022]

PHAC
- Summary of evidence supporting COVID-19 public health measures [08-31-2022]
- Accessing public health support for First Nations communities [08-05-2022]
- COVID-19 and people with disabilities in Canada [07-06-2022]
- Reducing COVID-19 risk in community settings: a tool for operators [02-10-2022]
- At home: using ventilation and filtration to reduce the risk of aerosol transmission of COVID-19 [12-15-2021]

WHO
- WHO mass gathering COVID-19 risk assessment tool: generic events, version 3 [06-16-2022]

CDC
- Isolation and precautions for people with COVID-19 [08-11-2022]

UK
- Living safely with respiratory infections, including COVID-19 [06-16-2022]

Businesses/Workplaces

Ontario Ministry of Health
- COVID-19 public health measures and advice [no date]
- COVID-19 and workplace health and safety [09-14-2022]
- Outbreak guidance: workplace and living settings for seasonal international agriculture workers (IAWs) [09-08-2022]

WHO
- Preventing and mitigating COVID-19 at work [05-19-2021]

CDC
- Specific settings [05-27-2022]
Protecting workers: guidance on mitigating and preventing the spread of COVID-19 in the workplace [08-13-2021]

Reducing the spread of respiratory infections, including COVID-19, in the workplace [06-10-2022]

Masks (Non-Medical)

Ontario Ministry of Health
- Face coverings and face masks [09-07-2022]

PHAC
- COVID-19 mask use: advice for community settings [04-22-2022]

WHO

CDC
- Your guide to masks [09-09-2022]

ECDC
- Considerations for the use of face masks in the community in the context of the SARS-CoV-2 Omicron variant of concern [02-07-2022]

UK
- Living safely with respiratory infections, including COVID-19: when to consider wearing a face covering or a face mask [06-16-2022]
- The Disabled Persons Transport Advisory Committee (DPTAC) position on face coverings [03-22-2021]